Core Insights - Cellectis is focusing on advancing its late-stage allogeneic CAR-T therapies, particularly lasme-cel and eti-cel, with significant clinical trials and partnerships expected to drive growth in 2026 [2][3][4]. Clinical Development - The pivotal Phase 2 trial for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has commenced, with interim data anticipated in Q4 2026 [2][3]. - Lasme-cel has shown a 68% overall response rate (ORR) and a 56% complete remission rate in early trials, indicating strong efficacy [5]. - The NATHALI-01 trial for eti-cel in relapsed/refractory non-Hodgkin lymphoma (NHL) reported an 88% ORR and a 63% complete remission rate, with further data expected in Q4 2026 [6]. Strategic Partnerships - Cellectis is collaborating with AstraZeneca to develop up to 10 novel cell and gene therapy products targeting high unmet medical needs, leveraging Cellectis' gene editing and manufacturing capabilities [4]. Financial Position - The company projects that its cash reserves will sustain operations into the second half of 2027, indicating a stable financial outlook [8]. Upcoming Events - Cellectis management will participate in the J.P. Morgan Healthcare Conference from January 12-15, 2026, for investor meetings [9].

Core Insights - Cellectis presented encouraging updated data for its eti-cel product candidate at the 67th Annual Meeting of the American Society of Hematology, showing a promising overall response rate of 88% and a complete response rate of 63% in patients with relapsed/refractory non-Hodgkin lymphoma [1][2][9] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform, with a unique allogeneic approach for CAR T immunotherapies [6][7] Clinical Trial Details - The eti-cel candidate is the first allogeneic dual CAR-T targeting CD20 and CD22 simultaneously, currently in Phase 1 of the NATHALI-01 clinical trial for patients who have undergone at least two lines of therapy [2][4] - Preliminary results from the trial indicate an overall response rate of 88% and a complete response rate of 63% based on a sample size of 8 patients [2][9] Future Directions - The company plans to investigate the impact of low dose Interleukin-2 (IL-2) support on the efficacy of eti-cel and will begin recruiting patients for the IL-2 support cohort in Q1 2026 [4][5][9] - Cellectis expects to present the full Phase 1 dataset in 2026 [5][9] Additional Findings - In vivo data suggest that low dose IL-2 support can enhance the expansion and persistence of CAR-T cells, potentially boosting efficacy without increasing toxicity [3][4]